Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. ANET
3. NKE
4. PANW
5. CL
6. SNDK
7. TAP
8. DELL
9. ROIV
10. HUBS

Go back to Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days

Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days

July 28, 2026 8:30 AM EDT

Delivery of the Bundibugyo viral antigens to Fondazione Biotecnopolo di Siena (FBS) and Scripps Research demonstrates C1's potential to accelerate vaccine and monoclonal antibody development, expand platform adoption, and create future commercial opportunities

JUPITER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (Dyadic or the Company), d/b/a Dyadic Applied BioSolutions, today announced that, within approximately 15 days of receiving the plasmids, it developed stable pools of C1 cell lines and manufactured and initially purified two Scripps-designed Bundibugyo ebolavirus recombinant protein antigens.

In response to the active Bundibugyo ebolavirus... More